Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age

[1] Chapman R(2020)Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: a modelling analysis Vaccine 38 7138-7145

[2] Sutton K(2018)Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15 Lancet Glob Health 6 e744-e757

[3] Dillon-Murphy D(2013)The pneumococcus: epidemiology, microbiology, and pathogenesis Cold Spring Harb Perspect Med 3 1191-1210

[4] Patel S(2016)Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Infect Dis 18 419-944

[5] Hilton B(2020)A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral streptococcus MBio 15 933-309

[6] Farkouh R(2015)Pneumococcal serotype evolution in Western Europe BMC Infect Dis 13 301-451

[7] Wahl B(2009)Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001–2007 Euro Surveill 15 441-366

[8] O’Brien KL(2016)Pneumococcal vaccination strategies. An update and perspective Ann Am Thorac Soc 18 359-75

[9] Greenbaum A(2021)Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges Expert Rev Vaccines 33 68-1732

[10] Majumder A(2015)Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance Lancet Infect Dis 6 1724-5079

[1] Chapman R(2020)Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: a modelling analysis Vaccine 38 7138-7145

[2] Sutton K(2018)Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15 Lancet Glob Health 6 e744-e757

[3] Dillon-Murphy D(2013)The pneumococcus: epidemiology, microbiology, and pathogenesis Cold Spring Harb Perspect Med 3 1191-1210

[4] Patel S(2016)Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Infect Dis 18 419-944

[5] Hilton B(2020)A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral streptococcus MBio 15 933-309

[6] Farkouh R(2015)Pneumococcal serotype evolution in Western Europe BMC Infect Dis 13 301-451

[7] Wahl B(2009)Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001–2007 Euro Surveill 15 441-366

[8] O’Brien KL(2016)Pneumococcal vaccination strategies. An update and perspective Ann Am Thorac Soc 18 359-75

[9] Greenbaum A(2021)Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges Expert Rev Vaccines 33 68-1732

[10] Majumder A(2015)Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance Lancet Infect Dis 6 1724-5079